Skip to main content

Advertisement

SpringerLink
Log in

Comparison of reduced-intensity/toxicity conditioning regimens for umbilical cord blood transplantation for lymphoid malignancies

  • Article
  • Published:
Bone Marrow Transplantation Submit manuscript

Abstract

To investigate which reduced-intensity conditioning (RIC)/reduced-toxicity conditioning (RTC) is superior for umbilical cord blood transplantation (UCBT) for lymphoid malignancies, we retrospectively compared three widely used RIC/RTC regimens: fludarabine/melphalan/total body irradiation (FM-TBI, n = 524), fludarabine/cyclophosphamide/total body irradiation (FC-TBI, n = 96), and fludarabine/busulfan/total body irradiation or melphalan (FB-based, n = 159). Among patients with acute lymphoblastic leukemia (ALL) (n = 314), there were no differences in overall survival (OS) by conditioning regimen. Among patients with malignant lymphoma (ML) (n = 465), FM-TBI and FC-TBI regimens had similar OS, whereas FB-based regimen had lower OS (hazard ratio [HR], 1.73; P < 0.01) than did FM-TBI regimen due to higher non-relapse mortality (HR, 1.72; P = 0.02). In addition, mycophenolate mofetil-containing GVHD prophylaxis was associated with better OS than methotrexate-containing GVHD prophylaxis among patients who received FM-TBI (HR, 0.65; P = 0.03) and FC-TBI (HR, 0.25; P < 0.01) regimens due to a decreased relapse risk. In summary, our results suggest that all three RIC/RTC regimens have comparable clinical outcomes in ALL, while the FM-TBI or FC-TBI regimens combined with mycophenolate mofetil-containing GVHD prophylaxis is preferable in RIC/RTC-UCBT for ML. Large prospective studies are warranted to confirm these results.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Outcomes by conditioning regimen.

Similar content being viewed by others

References

  1. Rocha V, Labopin M, Sanz G, Arcese W, Schwerdtfeger R, Bosi A, et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med. 2004;351:2276–85.

    CAS  PubMed  Google Scholar 

  2. Eapen M, Rocha V, Sanz G, Scaradavou A, Zhang MJ, Arcese W, et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol. 2010;11:653–60.

    PubMed  PubMed Central  Google Scholar 

  3. Cutler C, Ballen K. Reduced-intensity conditioning and umbilical cord blood transplantation in adults. Bone Marrow Transpl. 2009;44:667–71.

    CAS  Google Scholar 

  4. Barker JN, Weisdorf DJ, DeFor TE, Blazar BR, Miller JS, Wagner JE. Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood. 2003;102:1915–9.

    CAS  PubMed  Google Scholar 

  5. Oran B, Wagner JE, DeFor TE, Weisdorf DJ, Brunstein CG. Effect of conditioning regimen intensity on acute myeloid leukemia outcomes after umbilical cord blood transplantation. Biol Blood Marrow Transpl. 2011;17:1327–34.

    Google Scholar 

  6. Somers JA, Braakman E, van der Holt B, Petersen EJ, Marijt EW, Huisman C, et al. Rapid induction of single donor chimerism after double umbilical cord blood transplantation preceded by reduced intensity conditioning: results of the HOVON 106 phase II study. Haematologica. 2014;99:1753–61.

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Rio B, Chevret S, Vigouroux S, Chevallier P, Furst S, Sirvent A, et al. Decreased nonrelapse mortality after unrelated cord blood transplantation for acute myeloid leukemia using reduced-intensity conditioning: a prospective phase II multicenter trial. Biol Blood Marrow Transpl. 2015;21:445–53.

    Google Scholar 

  8. Uchida N, Wake A, Takagi S, Yamamoto H, Kato D, Matsuhashi Y, et al. Umbilical cord blood transplantation after reduced-intensity conditioning for elderly patients with hematologic diseases. Biol Blood Marrow Transpl. 2008;14:583–90.

    Google Scholar 

  9. Brunstein CG, Eapen M, Ahn KW, Appelbaum FR, Ballen KK, Champlin RE, et al. Reduced-intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes. Blood. 2012;119:5591–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Yamamoto H, Uchida N, Matsuno N, Kon A, Nishida A, Ota H, et al. I.v. BU/fludarabine plus melphalan or TBI in unrelated cord blood transplantation for high-risk hematological diseases. Bone Marrow Transpl. 2015;50:607–9.

    CAS  Google Scholar 

  11. Yamamoto H, Uchida N, Yuasa M, Kageyama K, Ota H, Kaji D, et al. A novel reduced-toxicity myeloablative conditioning regimen using full-dose busulfan, fludarabine, and melphalan for single cord blood transplantation provides durable engraftment and remission in nonremission myeloid malignancies. Biol Blood Marrow Transpl. 2016;22:1844–50.

    CAS  Google Scholar 

  12. Barker JN, Kurtzberg J, Ballen K, Boo M, Brunstein C, Cutler C, et al. Optimal practices in unrelated donor cord blood transplantation for hematologic malignancies. Biol Blood Marrow Transpl. 2017;23:882–96.

    Google Scholar 

  13. Terakura S, Kuwatsuka Y, Yamasaki S, Wake A, Kanda J, Inamoto Y, et al. GvHD prophylaxis after single-unit reduced intensity conditioning cord blood transplantation in adults with acute leukemia. Bone Marrow Transpl. 2017;52:1261–7.

    CAS  Google Scholar 

  14. Bachanova V, Verneris MR, DeFor T, Brunstein CG, Weisdorf DJ. Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation. Blood. 2009;113:2902–5.

    CAS  PubMed  Google Scholar 

  15. Rodrigues CA, Sanz G, Brunstein CG, Sanz J, Wagner JE, Renaud M, et al. Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol. 2009;27:256–63.

    PubMed  Google Scholar 

  16. Xavier E, Cornillon J, Ruggeri A, Chevallier P, Cornelissen JJ, Andersen NS, et al. Outcomes of cord blood transplantation using reduced-intensity conditioning for chronic lymphocytic leukemia: a study on behalf of Eurocord and Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation, and the Societe Francaise de Greffe de Moelle et Therapie Cellulaire. Biol Blood Marrow Transpl. 2015;21:1515–23.

    Google Scholar 

  17. Paviglianiti A, Tozatto Maio K, Rocha V, Gehlkopf E, Milpied N, Esquirol A, et al. Outcomes of advanced hodgkin lymphoma after umbilical cord blood transplantation: a Eurocord and EBMT Lymphoma and Cellular Therapy & Immunobiology Working Party Study. Biol Blood Marrow Transpl. 2018;24:2265–70.

    Google Scholar 

  18. Atsuta Y, Suzuki R, Yoshimi A, Gondo H, Tanaka J, Hiraoka A, et al. Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System. Int J Hematol. 2007;86:269–74.

    PubMed  Google Scholar 

  19. Atsuta Y. Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data). Int J Hematol. 2016;103:3–10.

    PubMed  Google Scholar 

  20. Kanda J. Scripts for TRUMP data analyses. Part II (HLA-related data): statistical analyses specific for hematopoietic stem cell transplantation. Int J Hematol. 2016;103:11–19.

    CAS  PubMed  Google Scholar 

  21. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transpl. 1995;15:825–8.

    CAS  Google Scholar 

  22. Sullivan KM, Shulman HM, Storb R, Weiden PL, Witherspoon RP, McDonald GB, et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood. 1981;57:267–76.

    CAS  PubMed  Google Scholar 

  23. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695–706.

    CAS  PubMed  Google Scholar 

  24. Scrucca L, Santucci A, Aversa F. Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transpl. 2007;40:381–7.

    CAS  Google Scholar 

  25. Klein JP, Rizzo JD, Zhang MJ, Keiding N. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: unadjusted analysis. Bone Marrow Transpl. 2001;28:909–15.

    CAS  Google Scholar 

  26. Cox DR. Regression models and life-tables. J R Stat Soc Ser B (Methodol). 1972;34:187–220.

    Google Scholar 

  27. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509.

    Google Scholar 

  28. Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, et al. Validation and refinement of the disease risk index for allogeneic stem cell transplantation. Blood. 2014;123:3664–71.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transpl. 2013;48:452–8.

    CAS  Google Scholar 

  30. Abedin S, Peres E, Levine JE, Choi S, Yanik G, Couriel DR. Double umbilical cord blood transplantation after novel myeloablative conditioning using a regimen of fludarabine, busulfan, and total lymphoid irradiation. Biol Blood Marrow Transpl. 2014;20:2062–6.

    CAS  Google Scholar 

  31. Pascal L, Mohty M, Ruggeri A, Tucunduva L, Milpied N, Chevallier P, et al. Impact of rabbit ATG-containing myeloablative conditioning regimens on the outcome of patients undergoing unrelated single-unit cord blood transplantation for hematological malignancies. Bone Marrow Transpl. 2015;50:45–50.

    CAS  Google Scholar 

  32. Pascal L, Tucunduva L, Ruggeri A, Blaise D, Ceballos P, Chevallier P, et al. Impact of ATG-containing reduced-intensity conditioning after single- or double-unit allogeneic cord blood transplantation. Blood. 2015;126:1027–32.

    CAS  PubMed  Google Scholar 

  33. Khalil MMI, Messner HA, Lipton JH, Kim DD, Viswabandya A, Thyagu S, et al. Fludarabine and busulfan plus low-dose TBI as reduced intensity conditioning in older patients undergoing allogeneic hematopoietic cell transplant for myeloid malignancies. Ann Hematol. 2018;97:1975–85.

    CAS  PubMed  Google Scholar 

  34. Hamilton BK, Liu Y, Hemmer MT, Majhail N, Ringden O, Kim D, et al. Inferior outcomes with cyclosporine and mycophenolate mofetil after myeloablative allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2019;25:1744–55.

    CAS  Google Scholar 

  35. Chhabra S, Liu Y, Hemmer MT, Costa L, Pidala JA, Couriel DR, et al. Comparative analysis of calcineurin inhibitor-based methotrexate and mycophenolate mofetil-containing regimens for prevention of graft-versus-host disease after reduced-intensity conditioning allogeneic transplantation. Biol Blood Marrow Transpl. 2019;25:73–85.

    CAS  Google Scholar 

  36. Perkins J, Field T, Kim J, Kharfan-Dabaja MA, Fernandez H, Ayala E, et al. A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis. Biol Blood Marrow Transpl. 2010;16:937–47.

    CAS  Google Scholar 

  37. Ram R, Yeshurun M, Vidal L, Shpilberg O, Gafter-Gvili A. Mycophenolate mofetil vs. methotrexate for the prevention of graft-versus-host-disease-systematic review and meta-analysis. Leuk Res. 2014;38:352–60.

    CAS  PubMed  Google Scholar 

  38. Hamilton BK, Rybicki L, Dean R, Majhail NS, Haddad H, Abounader D, et al. Cyclosporine in combination with mycophenolate mofetil versus methotrexate for graft versus host disease prevention in myeloablative HLA-identical sibling donor allogeneic hematopoietic cell transplantation. Am J Hematol. 2015;90:144–8.

    CAS  PubMed  Google Scholar 

  39. Terakura S, Wake A, Inamoto Y, Murata M, Sakai R, Yamaguchi T, et al. Exploratory research for optimal GvHD prophylaxis after single unit CBT in adults: short-term methotrexate reduced the incidence of severe GvHD more than mycophenolate mofetil. Bone Marrow Transpl. 2017;52:423–30.

    CAS  Google Scholar 

  40. Shimoni A, Hardan I, Shem-Tov N, Rand A, Herscovici C, Yerushalmi R, et al. Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan. Leukemia. 2007;21:2109–16.

    CAS  PubMed  Google Scholar 

  41. Kekre N, Marquez-Malaver FJ, Cabrero M, Pinana J, Esquirol A, Soiffer RJ, et al. Fludarabine/Busulfan versus fludarabine/melphalan conditioning in patients undergoing reduced-intensity conditioning hematopoietic stem cell transplantation for lymphoma. Biol Blood Marrow Transpl. 2016;22:1808–15.

    CAS  Google Scholar 

Download references

Acknowledgements

We thank all staff members of the collaborating institutions of the Japan Society for Hematopoietic Cell Transplantation (JSHCT) and all the members of the data management committees of the JSHCT. This work was supported in part by the Practical Research Project for Allergic Diseases and Immunology (Research Technology of Medical Transplantation) from the Japan Agency for Medical Research and Development, AMED, under grant number 19ek0510023h0002.

Donor/Source Working Group of the Japan Society for Hematopoietic Cell Transplantation

Junya Kanda16, Hiroatsu Ago17, Yoshiko Atsuta18,19, Kiyotoshi Imai20, Naoyuki Uchida21, Koji Kato22, Shunichi Kato23, Yoshinobu Kanda24, Yachiyo Kuwatsuka25, Takeshi Kobayashi26, Masashi Sawa27, Kazutaka Sunami28, Sachiko Seo29, Masatsugu Tanaka30, Shuichi Taniguchi21, Ken Tabuchi31, Nobuhiro Tsukada32, Seitaro Terakura33, Yasuyuki Nagata34, Satoshi Nishiwaki25, Naoto Fujita35, Ryosuke Matsuno36, Kimikazu Matsumoto37, Shin Mitamura38, Hidetsugu Mihara39, Koichi Miyamura40, Yasuo Morishima41, Kimikazu Yakushijin42, Nobuhiro Watanabe43, Ken Ishiyama44, Fumihiko Kimura45, Koji Nagafuji46, Toshio Yabe47, Nobuhiko Imahashi48, Yasuhito Nannya49, Moritaka Goto50, Takaaki Konuma51, Kotaro Miyao43, Naoki Kurita52, Yoshihiro Inamoto53, Shinichi Kobayashi45, Koji Kawamura24, Tsunehiko Komatsu54, Kazuma Ohyashiki55, Keisuke Kato56, Kentaro Kohno57, Tsuneaki Hirakawa58, Shinichiro Fujiwara59, Jiro Inagaki60, Masahito Tokunaga61, Tatsunori Goto40, Ayako Kobayashi45, Yasuhiko Shibasaki62, Susumu Tanoue63, Hiromi Hayashi64, Masahiro Hirayama65, Mizuki Watanabe16, Hiroaki Araie66, Taiki Ando30, Yosuke Okada45, Seiko Kato51, Yuki Takeuchi43, Takahiro Fujino53, Takaya Mitsuyoshi16

Author information

Authors and Affiliations

  1. Department of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan

    Nobuhiko Imahashi

  2. Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan

    Seitaro Terakura

  3. Department of Hematology, Kawasaki Medical School, Kurashiki, Japan

    Eisei Kondo

  4. Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan

    Shinichi Kako

  5. Department of Hematology, Toranomon Hospital, Tokyo, Japan

    Naoyuki Uchida

  6. Department of Hematology, Nagano Red Cross Hospital, Nagano, Japan

    Hikaru Kobayashi

  7. Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan

    Yoshihiro Inamoto & Takahiro Fukuda

  8. Division of Hematology, Shinshu University School of Medicine, Matsumoto, Japan

    Hitoshi Sakai

  9. Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan

    Masatsugu Tanaka

  10. Department of Hematology, Osaka International Cancer Institute, Osaka, Japan

    Jun Ishikawa

  11. Department of Transfusion Medicine, Tokyo Metropolitan Tama Medical Center, Fuchu, Japan

    Yasuji Kozai

  12. Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan

    Ken-ichi Matsuoka

  13. Preparation Department, Japanese Red Cross Kinki Block Blood Center, Osaka, Japan

    Takafumi Kimura

  14. Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan

    Yoshiko Atsuta

  15. Department of Healthcare Administration, Nagoya University Graduate School of Medicine, Nagoya, Japan

    Yoshiko Atsuta

  16. Department of Hematology and Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan

    Junya Kanda, Junya Kanda, Mizuki Watanabe & Takaya Mitsuyoshi

  17. Department of Hematology and Oncology, Shimane Prefectural Central Hospital, Izumo, Japan

    Hiroatsu Ago

  18. Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan

    Yoshiko Atsuta

  19. Department of Healthcare Administration, Nagoya University Graduate School of Medicine, Nagoya, Japan

    Yoshiko Atsuta

  20. Department of Hematology, Otaru General Hospital, Otaru, Japan

    Kiyotoshi Imai

  21. Department of Hematology, Toranomon Hospital, Tokyo, Japan

    Naoyuki Uchida & Shuichi Taniguchi

  22. Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan

    Koji Kato

  23. Division of Cell Transplantation and Regenerative Medicine, Department of Innovative Medical Science, Tokai University School of Medicine, Isehara, Japan

    Shunichi Kato

  24. Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan

    Yoshinobu Kanda & Koji Kawamura

  25. Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan

    Yachiyo Kuwatsuka & Satoshi Nishiwaki

  26. Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan

    Takeshi Kobayashi

  27. Department of Hematology and Oncology, Anjo Kosei Hospital, Anjo, Japan

    Masashi Sawa

  28. Department of Hematology, National Hospital Organization Okayama Medical Center, Okayama, Japan

    Kazutaka Sunami

  29. Department of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan

    Sachiko Seo

  30. Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan

    Masatsugu Tanaka & Taiki Ando

  31. Department of Pediatrics and Data Center, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan

    Ken Tabuchi

  32. Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan

    Nobuhiro Tsukada

  33. Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan

    Seitaro Terakura

  34. Department of Hematology, Hamamatsu University School of Medicine, Hamamatsu, Japan

    Yasuyuki Nagata

  35. Department of Pediatrics, Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital, Hiroshima, Japan

    Naoto Fujita

  36. Department of Pediatrics, Showa University Fujigaoka Hospital, Yokohama, Japan

    Ryosuke Matsuno

  37. Children’s Cancer Center, National Center for Child Health and Development, Tokyo, Japan

    Kimikazu Matsumoto

  38. Nova Biomedical K.K., Tokyo, Japan

    Shin Mitamura

  39. Division of Hematology, Aichi Medical University School of Medicine, Nagakute, Japan

    Hidetsugu Mihara

  40. Department of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan

    Koichi Miyamura & Tatsunori Goto

  41. Department of Promotion for Blood and Marrow Transplantation, Aichi Medical University School of Medicine, Nagakute, Japan

    Yasuo Morishima

  42. Department of Medical Oncology and Hematology, Kobe University Hospital, Kobe, Japan

    Kimikazu Yakushijin

  43. Department of Pediatrics, Meitetsu Hospital, Nagoya, Japan

    Nobuhiro Watanabe, Kotaro Miyao & Yuki Takeuchi

  44. Department of Hematology, Kanazawa University Hospital, Kanazawa, Japan

    Ken Ishiyama

  45. Division of Hematology, National Defense Medical College, Tokorozawa, Japan

    Fumihiko Kimura, Shinichi Kobayashi, Ayako Kobayashi & Yosuke Okada

  46. Division of Hematology and Oncology, Kurume University Hospital, Kurume, Japan

    Koji Nagafuji

  47. Laboratory Department, Japanese Red Cross Kanto-Koshinetsu Block Blood Center, Tokyo, Japan

    Toshio Yabe

  48. Department of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan

    Nobuhiko Imahashi

  49. Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan

    Yasuhito Nannya

  50. First Department of Internal Medicine, Tokyo Medical University, Tokyo, Japan

    Moritaka Goto

  51. Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan

    Takaaki Konuma & Seiko Kato

  52. Department of Hematology, University of Tsukuba, Tsukuba, Japan

    Naoki Kurita

  53. Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan

    Yoshihiro Inamoto & Takahiro Fujino

  54. Department of Hematology and Rheumatology, Teikyo University Chiba Medical Center, Chiba, Japan

    Tsunehiko Komatsu

  55. Department of Hematology, Tokyo Medical University, Tokyo, Japan

    Kazuma Ohyashiki

  56. Division of Pediatric Hematology and Oncology, Ibaraki Children’s Hospital, Mito, Japan

    Keisuke Kato

  57. Department of Hematology/Oncology, Japan Community Health Care Organization Kyusyu Hospital, Kitakyushu, Japan

    Kentaro Kohno

  58. Hematology and Oncology, St. Marianna University School of Medicine, Kawasaki, Japan

    Tsuneaki Hirakawa

  59. Division of Hematology, Jichi Medical University, Shimotsuke-shi, Japan

    Shinichiro Fujiwara

  60. Department of Pediatrics, Kitakyushu City Yahata Hospital, Kitakyushu, Japan

    Jiro Inagaki

  61. Department of Hematology, Imamura General Hospital, Kagoshima, Japan

    Masahito Tokunaga

  62. Stem Cell Transplantation, Niigata University Medical and Dental Hospital, Niigata, Japan

    Yasuhiko Shibasaki

  63. Division of Oncology and Hematology, Jikei University, Tokyo, Japan

    Susumu Tanoue

  64. Eurocord, Hospital Saint Louis AP-HP, IUH University Paris VII, Paris, France

    Hiromi Hayashi

  65. Department of Pediatrics, Mie University, Tsu, Japan

    Masahiro Hirayama

  66. Department of Hematology and Oncology, University of Fukui, Yoshida-gun, Japan

    Hiroaki Araie

Authors
  1. Nobuhiko Imahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Seitaro Terakura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eisei Kondo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shinichi Kako
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Naoyuki Uchida
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hikaru Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yoshihiro Inamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hitoshi Sakai
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Masatsugu Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jun Ishikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yasuji Kozai
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Ken-ichi Matsuoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Takafumi Kimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Takahiro Fukuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Yoshiko Atsuta
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Junya Kanda
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

for the Donor/Source Working Group of the Japan Society for Hematopoietic Cell Transplantation

  • Junya Kanda
  • , Hiroatsu Ago
  • , Yoshiko Atsuta
  • , Kiyotoshi Imai
  • , Naoyuki Uchida
  • , Koji Kato
  • , Shunichi Kato
  • , Yoshinobu Kanda
  • , Yachiyo Kuwatsuka
  • , Takeshi Kobayashi
  • , Masashi Sawa
  • , Kazutaka Sunami
  • , Sachiko Seo
  • , Masatsugu Tanaka
  • , Shuichi Taniguchi
  • , Ken Tabuchi
  • , Nobuhiro Tsukada
  • , Seitaro Terakura
  • , Yasuyuki Nagata
  • , Satoshi Nishiwaki
  • , Naoto Fujita
  • , Ryosuke Matsuno
  • , Kimikazu Matsumoto
  • , Shin Mitamura
  • , Hidetsugu Mihara
  • , Koichi Miyamura
  • , Yasuo Morishima
  • , Kimikazu Yakushijin
  • , Nobuhiro Watanabe
  • , Ken Ishiyama
  • , Fumihiko Kimura
  • , Koji Nagafuji
  • , Toshio Yabe
  • , Nobuhiko Imahashi
  • , Yasuhito Nannya
  • , Moritaka Goto
  • , Takaaki Konuma
  • , Kotaro Miyao
  • , Naoki Kurita
  • , Yoshihiro Inamoto
  • , Shinichi Kobayashi
  • , Koji Kawamura
  • , Tsunehiko Komatsu
  • , Kazuma Ohyashiki
  • , Keisuke Kato
  • , Kentaro Kohno
  • , Tsuneaki Hirakawa
  • , Shinichiro Fujiwara
  • , Jiro Inagaki
  • , Masahito Tokunaga
  • , Tatsunori Goto
  • , Ayako Kobayashi
  • , Yasuhiko Shibasaki
  • , Susumu Tanoue
  • , Hiromi Hayashi
  • , Masahiro Hirayama
  • , Mizuki Watanabe
  • , Hiroaki Araie
  • , Taiki Ando
  • , Yosuke Okada
  • , Seiko Kato
  • , Yuki Takeuchi
  • , Takahiro Fujino
  •  & Takaya Mitsuyoshi

Contributions

NI designed the research, analyzed the data, and wrote the manuscript. ST and JK analyzed the data and helped write the manuscript. NU, HK, TF, HS, MT, JI, YK, and KM collected the patient data. TK, TF, and YA supervised the data management. EK, SK, and JK designed and supervised the research. All authors reviewed and approved the final version of the manuscript.

Corresponding author

Correspondence to Nobuhiko Imahashi.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Members of the Donor/Source Working Group of the Japan Society for Hematopoietic Cell Transplantation are listed below Acknowledgements.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Imahashi, N., Terakura, S., Kondo, E. et al. Comparison of reduced-intensity/toxicity conditioning regimens for umbilical cord blood transplantation for lymphoid malignancies. Bone Marrow Transplant 55, 2098–2108 (2020). https://doi.org/10.1038/s41409-020-0905-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-020-0905-6

  • Springer Nature Limited

This article is cited by

Search

Navigation